As shown in Fig. 1M, N, the regulation of YAP1 by CK2 might be a common mechanism as the treatment of Silmitasertib or the depletion of CK2α significantly reduced YAP1 protein levels in various cancer cells including lung cancer (H460 and A549), PDAC (PANC-1 and MIAPaCa-2), TNBC (MDA-MB-231), renal cancer (786-O and RCC4), HCC (Huh-7) and CRC (HCT-116 and LoVo). Here, YAP1 is linked to hepatocellular carcinoma.